You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新鋭醫藥(06108.HK)預計年度將錄得淨虧損大幅增加
格隆匯 01-08 20:38

格隆匯 1 月 8日丨新鋭醫藥(06108.HK)公佈,預期集團截至2020年12月31日止年度將錄得淨虧損大幅增加,而2019財政年度則錄得淨虧損約4410萬港元。

集團於2020財政年度的虧損主要由於(i)毛利減少,其主要原因是於2020年,根據中國部分地區新實施的藥品集中採購政策,集團二代頭孢產品(1.0g)下主要產品的平均售價降低;(ii)貿易活動因2020年爆發Covid-19大流行病而有所放緩,導致分佔集團一間聯營公司賽科國際醫療集團有限公司("賽科國際")的溢利減少;(iii)於2020財政年度就集團於賽科國際的權益確認減值虧損約2990萬港元(2019財政年度:約2090萬港元);(iv)於2020財政年度就集團貿易及其他應收款項確認預期信貸虧損撥備約3270萬港元(2019財政年度:約900萬港元),因預計集團長期未收回的貿易及其他應收款項的償還不確定性增加;及(v)於2020財政年度就持作出售資產確認減值虧損約760萬港元(2019財政年度:零)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account